Drugs Used in Parasomnia.
Study Goal
The researchers aimed to evaluate the role of pharmacologic treatments, including melatonin, in managing disorders of arousal (DOA) and rapid eye movement sleep behavior disorder (RBD).
Results Summary
The abstract notes that melatonin is commonly used for RBD treatment, suggesting its symptomatic efficacy, but does not provide specific outcome data. No comparative efficacy or adverse effects are detailed.
Population
Patients with disorders of arousal (DOA) or rapid eye movement sleep behavior disorder (RBD).
Effective Dosage
Not available
Duration
Not available
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
patient education and behavioral management | neutral | parasomnia | patient with parasomnia | - | represent the first treatment approaches | #1 |
pharmacologic treatment | neutral | disorders of arousal | - | - | may be useful | #2 |
benzodiazepines | neutral | disorders of arousal | - | - | most commonly used | #3 |
antidepressants | neutral | disorders of arousal | - | - | most commonly used | #4 |
clonazepam | neutral | rapid eye movement sleep behavior disorder | - | - | most commonly used | #5 |
melatonin | neutral | rapid eye movement sleep behavior disorder | - | - | most commonly used | #6 |
Patient education and behavioral management represent the first treatment approaches to the patient with parasomnia, especially in case of disorders of arousal (DOA). A pharmacologic treatment of DOA may be useful when episodes are frequent and persist despite resolution of predisposing factors, are associated with a high risk of injury, or cause significant impairment, such as excessive sleepiness. Approved drugs for DOA are still lacking. The most commonly used medications are benzodiazepines and antidepressants. The pharmacologic treatment of rapid eye movement sleep behavior disorder is symptomatic, and the most commonly used drugs are clonazepam and melatonin.